Genetic loci associated with delayed clearance of Plasmodium falciparum following artemisinin treatment in Southeast Asia
- PMID: 23248304
- PMCID: PMC3538248
- DOI: 10.1073/pnas.1211205110
Genetic loci associated with delayed clearance of Plasmodium falciparum following artemisinin treatment in Southeast Asia
Abstract
The recent emergence of artemisinin-resistant Plasmodium falciparum malaria in western Cambodia could threaten prospects for malaria elimination. Identification of the genetic basis of resistance would provide tools for molecular surveillance, aiding efforts to contain resistance. Clinical trials of artesunate efficacy were conducted in Bangladesh, in northwestern Thailand near the Myanmar border, and at two sites in western Cambodia. Parasites collected from trial participants were genotyped at 8,079 single nucleotide polymorphisms (SNPs) using a P. falciparum-specific SNP array. Parasite genotypes were examined for signatures of recent positive selection and association with parasite clearance phenotypes to identify regions of the genome associated with artemisinin resistance. Four SNPs on chromosomes 10 (one), 13 (two), and 14 (one) were significantly associated with delayed parasite clearance. The two SNPs on chromosome 13 are in a region of the genome that appears to be under strong recent positive selection in Cambodia. The SNPs on chromosomes 10 and 13 lie in or near genes involved in postreplication repair, a DNA damage-tolerance pathway. Replication and validation studies are needed to refine the location of loci responsible for artemisinin resistance and to understand the mechanism behind it; however, two SNPs on chromosomes 10 and 13 may be useful markers of delayed parasite clearance in surveillance for artemisinin resistance in Southeast Asia.
Conflict of interest statement
Conflict of interest statement: As a World Health Organization (WHO) staff member, P.R. is responsible for the views expressed in this publication, which do not necessarily represent the decisions, policy, or views of the WHO. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, and mention of trade names, commercial products, or organizations does not imply endorsement by the US Government.
Figures
References
-
- World Health Organization 2011. World Malaria Report 2011 (WHO, Geneva)
-
- World Health Organization 2001. Antimalarial Drug Combination Therapy. Report of a WHO Technical Consultation (WHO, Geneva)
-
- Alker AP, et al. Pfmdr1 and in vivo resistance to artesunate-mefloquine in falciparum malaria on the Cambodian-Thai border. Am J Trop Med Hyg. 2007;76(4):641–647. - PubMed
-
- Denis MB, et al. Surveillance of the efficacy of artesunate and mefloquine combination for the treatment of uncomplicated falciparum malaria in Cambodia. Trop Med Int Health. 2006;11(9):1360–1366. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 AI101713/AI/NIAID NIH HHS/United States
- K12 RR023250/RR/NCRR NIH HHS/United States
- K12RR023250/RR/NCRR NIH HHS/United States
- HHMI/Howard Hughes Medical Institute/United States
- 089275/WT_/Wellcome Trust/United Kingdom
- 090770/Z/09/Z/WT_/Wellcome Trust/United Kingdom
- 090532/WT_/Wellcome Trust/United Kingdom
- 090770/WT_/Wellcome Trust/United Kingdom
- HHSN261200800001C/RC/CCR NIH HHS/United States
- 098051/WT_/Wellcome Trust/United Kingdom
- G0600718/MRC_/Medical Research Council/United Kingdom
- HHSN261200800001E/CA/NCI NIH HHS/United States
- 093956/WT_/Wellcome Trust/United Kingdom
- G19/9/MRC_/Medical Research Council/United Kingdom
- 077012/Z/05/Z/WT_/Wellcome Trust/United Kingdom
- ImNIH/Intramural NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
